Zobrazit v EDS

Treatment of Breast Cancer-Related Lymphedema with Adipose-Derived Regenerative Cells and Fat Grafts: A Feasibility and Safety Study: A feasibility and safety study

Uloženo v:
Podrobná bibliografie
Název: Treatment of Breast Cancer-Related Lymphedema with Adipose-Derived Regenerative Cells and Fat Grafts: A Feasibility and Safety Study: A feasibility and safety study
Autoři: Toyserkani, Navid Mohamadpour, Jensen, Charlotte Harken, Andersen, Ditte Caroline, Sheikh, Søren Paludan, Sørensen, Jens Ahm
Zdroj: Stem Cells Transl Med
Stem Cells Translational Medicine, Vol 6, Iss 8, Pp 1666-1672 (2017)
Toyserkani, N M, Jensen, C H, Andersen, D C, Sheikh, S P & Sørensen, J A 2017, ' Treatment of breast cancer-related lymphedema with adipose-derived regenerative cells and fat grafts : A feasibility and safety study ', Stem Cells Translational Medicine, vol. 6, no. 8, pp. 1666-1672 . https://doi.org/10.1002/sctm.17-0037
Informace o vydavateli: Oxford University Press (OUP), 2017.
Rok vydání: 2017
Témata: Adult, Medicine (General), Cells, Breast Cancer Lymphedema, Human Clinical Articles, Mesenchymal Stem Cell Transplantation, 03 medical and health sciences, R5-920, 0302 clinical medicine, Mesenchymal Stem Cell Transplantation/adverse effects, Adipose-derived regenerative cells, Tissue Transplantation/adverse effects, Humans, Fat graft Authored by a member of, Lymphedema, Fat graft, Cells, Cultured, Aged, Cultured, QH573-671, Breast Cancer Lymphedema/therapy, Middle Aged, 3. Good health, Adipose‐derived regenerative cells, Adipose Tissue, Regenerative medicine, Tissue Transplantation, Feasibility Studies, Female, Adipose Tissue/cytology, Cytology
Popis: Breast cancer-related lymphedema (BCRL) is a debilitating late complication with a lack of treatment opportunities. Recent studies have suggested that mesenchymal stromal cells can alleviate lymphedema. Herein, we report the results from the first human pilot study with freshly isolated adipose-derived regenerative cells (ADRC) for treating lymphedema with 6 months follow-up. Ten BCRL patients were included. ADRC was injected directly into the axillary region, which was combined with a scar-releasing fat graft procedure. Primary endpoints were change in arm volume. Secondary endpoints were change in patient reported outcome and safety. The study is registered with ClinicalTrials.gov (NCT02592213). During follow-up, a small volume reduction was noted but was not significant. Five patients reduced their use of conservative management. Patient-reported outcomes improved significantly over time. ADRCs were well tolerated and only minor transient adverse events related to liposuction were noted. In this pilot study, a single injection of ADRC improved lymphedema based on patient-reported outcome measures, and there were no serious adverse events in the 6 months follow-up period. In addition, half of the patients reduced their use of conservative management. ADRC therapy is a promising interventional therapy for alleviating lymphedema, but results need to be confirmed in randomized clinical trials.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 2157-6580
2157-6564
DOI: 10.1002/sctm.17-0037
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/28653440
https://doaj.org/article/cd5b74184d6440278c85c128df05e436
http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002/sctm.17-0037
https://onlinelibrary.wiley.com/doi/abs/10.1002/sctm.17-0037
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.17-0037
https://core.ac.uk/display/92666435
https://pubmed.ncbi.nlm.nih.gov/28653440/
http://europepmc.org/articles/PMC5689749
https://portal.findresearcher.sdu.dk/da/publications/bae7ce08-7e14-4e4a-8051-31c3868e6346
https://doi.org/10.1002/sctm.17-0037
https://findresearcher.sdu.dk:8443/ws/files/125843858/Treatment_of_breast_cancer_related_lymphedema_with_adipose_derived_regenerative_cells_and_fat_grafts.pdf
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....59f4df861662dbbd4187cec83eec6d5a
Databáze: OpenAIRE
Popis
Abstrakt:Breast cancer-related lymphedema (BCRL) is a debilitating late complication with a lack of treatment opportunities. Recent studies have suggested that mesenchymal stromal cells can alleviate lymphedema. Herein, we report the results from the first human pilot study with freshly isolated adipose-derived regenerative cells (ADRC) for treating lymphedema with 6 months follow-up. Ten BCRL patients were included. ADRC was injected directly into the axillary region, which was combined with a scar-releasing fat graft procedure. Primary endpoints were change in arm volume. Secondary endpoints were change in patient reported outcome and safety. The study is registered with ClinicalTrials.gov (NCT02592213). During follow-up, a small volume reduction was noted but was not significant. Five patients reduced their use of conservative management. Patient-reported outcomes improved significantly over time. ADRCs were well tolerated and only minor transient adverse events related to liposuction were noted. In this pilot study, a single injection of ADRC improved lymphedema based on patient-reported outcome measures, and there were no serious adverse events in the 6 months follow-up period. In addition, half of the patients reduced their use of conservative management. ADRC therapy is a promising interventional therapy for alleviating lymphedema, but results need to be confirmed in randomized clinical trials.
ISSN:21576580
21576564
DOI:10.1002/sctm.17-0037